Based on the CROSS score with a range from 0 to 6, anti-MDA5+DM patients were classified as moderate risk (CROSS score = 0-2), high risk (CROSS score = 3-4), and very high risk (CROSS score = 5-6) for developing of RP-ILD, respectively (Table 2). Here, IFIH1 is linked to dermatomyositis.